Frankel Laboratory, Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel.
Curr Stem Cell Res Ther. 2013 Jul;8(4):333-9. doi: 10.2174/1574888x113089990001.
Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
最近的临床研究表明，免疫抑制疗法能够延缓 1 型糖尿病（T1D）炎症性胰岛炎的进展。该方法包括通过免疫抑制疗法耗尽致病性细胞，并通过输注自体造血祖细胞来支持恢复。这些临床移植的短期结果与 NOD 小鼠的预测相似：免疫抑制疗法不能有效地消除致糖尿病细胞，免疫内稳态的重置并不能抑制自身免疫。鼠模型表明，同种异体移植具有潜在的治愈作用，这是通过恢复有效的负调节机制实现的，能够持续和无限期地抑制自身免疫。
